Mipletamig Biosimilar – Anti-IL-3R subunit alpha;CD3e mAb – Research Grade

Introduction:
Mipletamig Biosimilar is a therapeutic antibody that targets the IL-3 receptor subunit alpha and CD3e protein. It is a research grade antibody that has shown promising results in preclinical studies and is currently undergoing clinical trials for potential therapeutic applications.

Structure:
Mipletamig Biosimilar is a monoclonal antibody (mAb) that is produced through recombinant DNA technology. It is a humanized antibody, meaning that it contains both human and mouse components, making it less likely to elicit an immune response in patients. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The heavy chains consist of constant and variable regions, while the light chains only have variable regions. The variable regions are responsible for binding to the IL-3 receptor subunit alpha and CD3e protein.

Activity:
Mipletamig Biosimilar specifically targets the IL-3 receptor subunit alpha and CD3e protein, which are both important components of the immune system. The IL-3 receptor subunit alpha is a cytokine receptor that is expressed on the surface of various immune cells, including T cells, B cells, and natural killer cells. The CD3e protein is a signaling molecule that is also found on the surface of T cells. By targeting these proteins, Mipletamig Biosimilar can modulate immune responses and potentially treat various immune-related disorders.

Application:
Mipletamig Biosimilar is being developed as a potential treatment for a variety of immune-related disorders, including autoimmune diseases, inflammatory disorders, and hematological malignancies. In preclinical studies, the antibody has shown promising results in reducing inflammation and suppressing immune responses. It has also been shown to have anti-tumor activity in certain types of cancer. Currently, Mipletamig Biosimilar is undergoing clinical trials to evaluate its safety and efficacy in treating these conditions.

Therapeutic Target: IL-3 Receptor Subunit Alpha
The IL-3 receptor subunit alpha is a cytokine receptor that is involved in the regulation of immune responses. It is expressed on the surface of various immune cells, including T cells, B cells, and natural killer cells. The binding of IL-3 to its receptor activates signaling pathways that promote cell growth and differentiation. Dysregulation of the IL-3 receptor subunit alpha has been implicated in various immune-related disorders, making it an attractive therapeutic target for Mipletamig Biosimilar.

Therapeutic Target: CD3e Protein
CD3e is a signaling molecule that is found on the surface of T cells. It plays a crucial role in T cell activation and proliferation. The binding of Mipletamig Biosimilar to CD3e can modulate T cell activity and potentially treat immune-related disorders. Dysregulation of CD3e has been linked to autoimmune diseases and hematological malignancies, further highlighting its importance as a therapeutic target for Mipletamig Biosimilar.

Conclusion:
Mipletamig Biosimilar is a promising therapeutic antibody that targets the IL-3 receptor subunit alpha and CD3e protein. Its unique structure and mechanism of action make it a potential treatment option for a variety of immune-related disorders. As it continues to undergo clinical trials, Mipletamig Biosimilar has the potential to improve the lives of patients suffering from these conditions.

ProteoGenix catalogue number PX-TA2200. For research use only.

Target: Mipletamig Biosimilar – Anti-IL-3R subunit alpha;CD3e mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >95% by SDS-PAGE; Buffer: 0.01M PBS, pH 7.4; Applications: WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet